Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.345 USD | -10.84% | -9.35% | -56.27% |
Mar. 26 | GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Feb. 01 | GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 4.62M |
---|---|---|---|---|---|
Net income 2024 * | -17M | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.31
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.75% |
1 day | -10.84% | ||
1 week | -9.35% | ||
Current month | -24.49% | ||
1 month | -23.46% | ||
3 months | -47.18% | ||
6 months | -56.27% | ||
Current year | -56.27% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Breen
CEO | Chief Executive Officer | 62 | 21-01-12 |
Manu Ohri
DFI | Director of Finance/CFO | 67 | 22-02-17 |
Jeffrey Miller
PRN | Corporate Officer/Principal | - | 22-12-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 78 | 23-04-30 | |
Bruce Wendel
BRD | Director/Board Member | 70 | 20-11-10 |
Rajesh Shrotriya
BRD | Director/Board Member | 79 | 21-01-12 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 3.345 | -10.84% | 10,397 |
24-04-25 | 3.752 | +2.78% | 3,434 |
24-04-23 | 3.65 | -3.44% | 10,589 |
24-04-22 | 3.78 | +2.44% | 3,469 |
24-04-19 | 3.69 | -2.90% | 5,907 |
Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-56.27% | 4.62M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- GTBP Stock